Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The transcobalamin receptor, also known as CD320, is a cell-surface receptor belonging to the low-density lipoprotein receptor family that mediates the cellular uptake of transcobalamin-bound vitamin B12 (cobalamin) via receptor-mediated endocytosis. It is expressed ubiquitously but is highly upregulated in actively proliferating cells, including various cancer cells, to support the high demand for vitamin B12 required for DNA synthesis and cell division. In addition to its role in nutrient uptake, CD320 is expressed on follicular dendritic cells and acts as a costimulator to promote germinal center B-cell differentiation and proliferation.
In oncology, CD320 is overexpressed in multiple cancers (such as multiple myeloma) and is being investigated as a target for antibody-drug conjugates, CAR-T cell therapies, and vitamin B12-conjugated therapeutics. Conversely, autoimmune B12 central deficiency is caused by pathogenic anti-CD320 autoantibodies that block the receptor at the blood-brain barrier, leading to severe neurological deficits despite normal systemic B12 levels. Therapeutic strategies targeting CD320 include experimental saporin-conjugated antibodies for cancer and novel lysosome-targeting chimeras designed to selectively degrade pathogenic anti-CD320 autoantibodies in autoimmune neurological conditions.
Receptor-mediated endocytosis of transcobalamin-bound cobalamin (vitamin B12); targeted drug delivery via conjugation to vitamin B12 or anti-CD320 antibodies; targeted degradation of pathogenic autoantibodies using lysosome-targeting chimeras (LYTACs).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcobalamin receptor (CD320).